Paper Details

  1. Home
  2. Paper Details

Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials.

Author: AokiY, Cid-RuzafaJ, CummingsK J, FeinS G, GoodmanS N, LeeS M, SulkowskiM S, WestE S

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Hepatitis C is a major cause of chronic liver disease in the United States. Combination therapy with interferon and ribavirin has proven more effective than interferon alone for treating previously untreated hepatitis C patients and those who experienced relapse after initial interferon treatment. However, the effectiveness of this combination therapy for patients who did not respond to previous interferon treatment is uncertain.
Paper Details　
Original Abstract of the Article :
Hepatitis C is the leading cause of chronic liver disease in the United States. Several trials have found that interferon and ribavirin combination therapy is more efficacious than interferon monotherapy for previously untreated patients and those who relapsed after prior interferon monotherapy, but...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1001/jama.285.2.193

データ提供：米国国立医学図書館（NLM）

Combating Hepatitis C: A Meta-Analysis of Re-Treatment Strategies

Hepatitis C, a viral infection affecting the liver, can have devastating consequences, leading to chronic liver disease and even liver failure. This research delves into the complexities of treating hepatitis C, particularly in cases where initial interferon monotherapy has failed. Imagine a desert oasis where a stubborn virus, hepatitis C, threatens to deplete the vital resources of the liver. The researchers conducted a meta-analysis to evaluate the effectiveness of combination therapy with interferon and ribavirin for patients who had not responded to interferon alone.

Interferon and Ribavirin: A Combined Force Against Hepatitis C

The meta-analysis revealed that combination therapy with interferon and ribavirin was more effective than interferon alone in treating hepatitis C in patients who had not responded to interferon monotherapy. This finding highlights the power of combining different therapeutic approaches, just as a well-equipped caravan traversing a harsh desert requires a range of tools and strategies to overcome challenges. This study suggests that combination therapy may offer a more effective solution for patients with hepatitis C who have not responded to previous treatments.

The Importance of Personalized Treatment Strategies

This research underscores the importance of personalized treatment strategies for hepatitis C, considering individual patient characteristics and response to therapy. The desert of hepatitis C is vast and diverse, requiring tailored approaches to effectively combat the virus. The findings of this study are valuable for clinicians, guiding them in selecting the most appropriate treatment options for their patients.

Dr.Camel's Conclusion

This meta-analysis provides strong evidence for the efficacy of combination therapy with interferon and ribavirin in treating hepatitis C in patients who have not responded to interferon monotherapy. The research highlights the importance of personalized treatment strategies, considering individual patient factors and response to therapy. The desert of hepatitis C research is vast and ever-evolving, but with continuous research and innovation, we are closer to finding effective and safe treatments for all those affected by this challenging disease.

Date :
  1. Date Completed 2001-03-15
  2. Date Revised 2019-07-01
Further Info :

Pubmed ID

11176813

DOI: Digital Object Identifier

10.1001/jama.285.2.193

Related Literature

Article Analysis
・Effective treatment of hepatitis c
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.